Fibroblast growth factor receptor inhibitors

Current Pharmaceutical Design

Volumn 19, Issue 4, 2013, Pages 687-701

  Suneel Kumar, B V S ^a   Narasu, Lakshmi ^b   Gundla, Rambabu ^a   Dayam, Raveendra ^a   Sarma, J A R P ^a  

^a GVK Biosciences TIE   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

Cancer; Cancer metabolism; FGFR mediated signaling; FGFR receptor; FGFR1 inhibitors

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 1,2,4 TRIAZINE DERIVATIVE; 1,6 NAPHTHYRIDIN 2 (1H) ONE; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; ANGIOGENESIS INHIBITOR; AZD 4547; BGJ 398; CALCIUM BINDING PROTEIN; DOVITINIB; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR; INDOLE DERIVATIVE; LENVATINIB; NAPHTHYRIDINE DERIVATIVE; NINTEDANIB; ORANTINIB; PHOSPHOLIPASE C GAMMA; PONATINIB; PROTEIN KINASE INHIBITOR; PYRIDO[2,3 D]PYRIMIDIN 7 (8H) ONE; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLO[2,1 F][1,2,4]TRIAZINE; SU 4984; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 1;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; ENDOMETRIUM CANCER; GENE MUTATION; HISTOPATHOLOGY; HUMAN; KIDNEY CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN STRUCTURE; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STOMACH CANCER; STRUCTURE ACTIVITY RELATION;

EID: 84876698366     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804581963     Document Type: Review

References (84)

1. Jorgen W, Kaisa H, Ellen MH. Fibroblast growth factors and their receptors in cancer. Biochem J 2011; 437: 199-213.
2. Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 1993; 60: 1-41.
3. Rajkumar T. Growth factors and growth factor receptors in cancer. Current science 2001; 81: 535-41.
4. Adnane J, Gaudray P, Dionne CA, et al. two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene 1991; 6: 659-63.
5. Bottcher RT, Niehrs C. Fibroblast growth factor signaling during early vertebrate development. Endocr Rev 2005; 26: 63-77.
6. Sleeman M, Fraser J, McDonald M, et al. Identification of a new fibroblast growth factor receptor, FGFR5. Gene 2001; 271: 171-82.
7. Groth C, Lardelli M. The structure and function of vertebrate fibroblast growth factor receptor 1. Int J DevBiol 2002; 46: 393-400.
8. Plotnikov AN, Schlessinger J, Hubbard SR, Mohammadi M. Structural basis for FGF receptor dimerization and activation. Cell 1999; 98: 641-50.
9. Galzie Z, Kinsella AR, Smith JA. Fibroblast growth factors and their receptors. Biochem Cell Biol 1997; 75: 669-85.
10. Forman-Kay JD, Pawson T, Diversity in protein recognition by PTB domains. CurrOpinStrucBiol 1999; 9: 690-95.
11. Faux CH, Turnley AM, Epa R, Cappai R, Bartlett PF. Interactions between fibroblast growth factors and Notch regulate neuronal differentiation. J Neurosci 2001; 21: 5587-96.
12. Gillespie LL, Chen G, Paterno GD. Cloning of a fibroblast growth factor receptor 1 splice variant from Xenopus embryos that lacks a protein kinase C site important for the regulation of receptor activity. J Biol Chem 1995; 270: 22758-63.
13. Givol D, Yayon A. Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J 1992; 6: 3362-69.
14. Haugsten EM, Wiedlocha A, Olsnes S, Wesche J. Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res 2010; 8: 1439-52.
15. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86: 356-61.
16. Wu ZL, Zhang L, Yabe T, et al. The involvement of heparan sulfate (HS) in FGF1/HS/FGFR1 signaling complex. J Biol Chem 2003; 278: 17121-29.
17. Chen PY, Friesel R. FGFR1 forms an FRS2-dependent complex with mTOR to regulate smooth muscle marker gene expression. BiochemBiophys Res Commun 2009; 382: 424-29.
18. ElbauomyElsheikh S, Green AR, Lambros MB, et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007; 9: R23.
19. Jacquemier J, Adelaide J, Parc P, et al. Expression of the FGFR1 gene in human breast-carcinoma cells. Int J Cancer 1994; 59: 373-378.
20. Jaakkola S, Salmikangas P, Nylund S, et al. Amplification of fgfr4 gene in human breast and gynecological cancers. Int J Cancer 1993; 54: 378-82.
21. Leung, HY, Gullick WJ, Lemoine NR. Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int. J. Cancer 1994; 59: 667-675.
22. Yamaguchi F, Saya H, Bruner JM, Morrison RS. Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci 1994; 91: 484-88.
23. Morrison RS, Yamaguchi F, Saya H, et al. Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas. J NeuroOncol 1994; 18: 207-216.
24. Li JJ, Huang YQ, Moscatelli D, Nicolaides A, Zhang WC, Friedman-Kien AE. Expression of fibroblast growth factors and their receptors in acquired immunodeficiency syndrome-associated Kaposi sarcoma tissue and derived cells. Cancer 1993; 72: 2253-59.
25. Courjal F, Cuny M, Simony-Lafontaine J, et al. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res 1997; 57: 4360-7.
26. Turner N, Pearson A, Sharpe R, et al. FGFR1 expression drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010; 70: 2085-94.
27. Freier K, Schwaenen C, Sticht C. Recurrent FGFR1 amplificationand high FGFR1 protein expression in oral squamous cellcarcinoma (OSCC). Oral Oncol 2007; 43: 60-6.
28. Ishizuka T, Tanabe C, Sakamoto H. Gene amplification profiling of esophageal squamous cell carcinoimas by DNA array CGH. BiochemBiophys Res Commun 2002; 296: 152-5.
29. Gorringe KL, Jacobs S, Thompson ER, et al. High resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res 2007; 13: 4731-9.
30. Dutt A, Ramos AH, Hammerman PS. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoA ONE 2011; 6: e20351.
31. Weiss J, Sos ML, Seidel D. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependencyin squamous cell lung cancer. SciTransl Med2010; 2: 62ra93.
32. Edwards J, Krishna NS, Witton CJ, Bartkett JM. Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 2003; 9: 5271-81.
33. Simon R, Richter J, Wagner U, et al. High-throughput tissue microarray analysis of 3p25 [RAF1] and 8p12 [FGFR1]copy number alterations in urinary bladder cancer. Cancer Res 2001; 61: 4514-9.
34. Yamaguchi F, Saya H, Bruner JM, Morrison RS. Differential expression of 2 fibroblast growth factor receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci USA 1994; 91: 484-8.
35. Missiaglia E, Selfe J, Hamdi M. Genomic imbalances in rhadomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development. Genes Chromosom Cancer 2009; 48: 455-67.
36. Kunii K, Davis L, Gorenstein J, et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008; 68: 2340-8.
37. Turner N, Lambros MB, Horlings HM, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010; 29: 2013-23.
38. Stacey SN, Manolescu P, Sulem P, et al. Common variants onchromosome 5p12 confer susceptibility to estrogen receptor positive breast cancer. Nat Genet 2008; 40: 704-6.
39. Nord H, Segersten U, Sundgren J. Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma. Int J Cancer 2009; 126: 1390-402.
40. Avet-Loiseau H, Facon T, Davier A, et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undeter mined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone de Myelome. Cancer Res 1999; 59: 4546-50.
41. Rosty C, Aubriot M-H, Cappellen D, et al. Clinical and biological characteristics of cervical neoplasias with FGFR3 mutations. Mol-Cance 2005; 4: 15.
42. Hernandez S, de Muga S, Agell L, et al. FGFR3 mutations in prostate cancer: association with low grade tumors. Mod Pathol 2009; 22: 848-56.
43. di ME, L'Hote CG, Kennedy W, et al. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type-and mutation-specific manner. Oncogene 2009; 28: 4306-16.
44. Dutt A, Salvesen HB, Chen TH, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. ProcNatlAcadSci USA 2008; 105: 8713-7.
45. Ornitz DM, Marie PJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dec 2002; 16: 1446-65.
46. Sotgia F, Whitaker-Menezes D, Martinez-Outschoorn UE, et al. Mitochondrial metabolism in cancer metastasis: Visualizing tumor cell mitochondria and the "Reverse Warburg Effect" in positive lymph node tissue. Cell Cycle 2012; 1: 1445-54
47. Bensinger SJ, Christofk HR. New aspects of the Warburg effect in cancer cell biology. Semin Cell DevBiol 2012; 23: 352-61
48. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452:230-3.
49. Hitosugi T, Kang S, Vander Heiden MG, et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal 2009; 2: ra73.
50. Dang CV. PKM2 tyrosine phosphorylation and glutamine metabolism signal a different view of the Warburg Effect. Sci Signal 2009; 2: pe75.
51. Mazurek S, Grimm H, Boschek CB, Vaupel P, Eigenbrodt E. Pyruvate kinase type M2: a crossroad in the tumormetabolome. Br J Nutrition 2002; 87: S23-9.
52. Mazureka S. Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells. The Int J Biochem & Cell Biology 2011; 43: 969-80.
53. Gozgit JM, Wong MJ, Moran L, et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFRamplified or mutated cancer models. Mol Cancer Ther 2012; 11: 690-9
54. Doebele RC, Conkling P, Traynor AM, et al. A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol. 2012; [Epub ahead of print].
55. Kim KB, Chesney J, Robinson D, Gardner H, Shi MM, Kirkwood JM. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res 201; 117: 7451-61
56. Boss DS, Glen H, Beijnen JH, et al. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer 2012; 106: 1598-604
57. Mani S, Vogelzang NJ, Bertucci D, Stadler WM, Schilsky RL, Ratain MJ. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer 2001; 92: 1567-76.
58. Gavine PR, Mooney L, Kilgour E, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012; 72: 2045-56
59. Suzuki Y, Saeki T, Aogi K, et al. A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane. Int J ClinOncol 2012; [Epub ahead of print].
60. Sun HD, Malabunga M, Tonra JR, et al. Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. Am J PhysiolEndocrinolMetab 2007; 292: 964-76.
61. Qing J, Du X, Chen Y, et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 2009; 119: 1216-29.
62. Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anti-cancer drug development. Nat Rev Cancer 2010; 10: 514-23.
63. Pardo OE, Latigo J, Jeffery RE, et al. The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res 2009; 15: 8645-651.
64. Cleo J, Connolly C, James M, et al. Discovery and Structure-Activity Studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Bioorg Med Chem Lett 1997; 7: 2415-20.
65. Schroeder MC, Hamby JM, Connolly CJ, et al. Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structureactivity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity. J Med Chem 2001; 44: 1915-26.
66. Mohammadi M, Froum S, Hamby JM, et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 1998; 17: 5896-904.
67. Sun L, Tran N, Tang F, et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem 1998; 41: 2588-603.
68. Sun L, Tran N, Liang C, et al. Design, synthesis, and evaluations of substituted 3-[(3-or 4-carboxyethylpyrrol-2-yl)methylidenyl] indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J Med Chem 1999; 42: 5120-30.
69. Sun L, Tran N, Liang C, et al. Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-R beta tyrosine kinases. J Med Chem 2000; 43: 2655-63.
70. Thompson AM, Delaney AM, Hamby JM, et al. Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases. J Med Chem 2005; 48: 4628-53.
71. Sun H. Fibroblast Growth Factor Receptor-1 Inhibitors and Methods of Treatment thereof, WO 2005/037235 A2.
72. Paul WM, Pascal F, Guido B, et al. Schnell, and Jeanette Wood; Anthranilic Acid Amides. A Novel Class of Antiangiogenic VEGF Receptor Kinase Inhibitors. J Med Chem 2002; 45: 5687-93.
73. Robert M. B, Xiaoping Z, Ligang Q, et al. Design, Synthesis, and Evaluation of Orally Active 4-(2,4-Difluoro-5-(methoxycarbamoyl) phenylamino)pyrrolo[2,1-f][1,2,4]triazines as Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Inhibitors. J Med Chem 2005; 48: 3991-4008.
74. Rajeev S. B, Zhen WC, Yong ZZ, et al. Discovery and Preclinical Studies of (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an In vivo Active Potent VEGFR-2 Inhibitor. J Med Chem 2006; 49: 2143-46.
75. Sylvester R. Klutchko, James M. Hamby, Diane H. Boschelli, et al. 2-Substituted Aminopyrido[2,3d]pyrimidin-7(8H)-ones. Structure-Activity Relationships against Selected Tyrosine Kinases and in vitro and in vivo Anticancer Activity; J Med Chem 1998; 41: 3276-792.
76. Blankley, Clifton J, Boschelli D, et al. Pyrido[2,3-D]Pyrimidines For Inhibiting Protein Tyrosine Kinase Mediated Cellular Proliferation; WO 96/34867 A1.
77. Booth, Richard, John, Dobrusin, Ellen, Myra Toogood, Peter, Laurence Vanderwel, Scott, Norman. 5 Alkylpyrido[2,3-D]Pyrimidines Tyrosine Kinase Inhibitors. WO 01/70741 A1.
78. Andrew MT, Gordon W, Rewcastle SL, et al. Synthesis and Structure Activity Relationships of 7-Substituted 3-(2,6-Dichlorophenyl)-1,6-naphthyridin-2(1H)-ones as Selective Inhibitors of pp60c-src. J Med Chem 2000; 43: 3134-47.
79. Bae JH, Lew ED, Yuzawa S, Tome F, Lax I, Schlessinger J. The Selectivity of Receptor Tyrosine Kinase Signaling Is Controlled by a Secondary SH2 Domain Binding Site. Cell 2009; 138: 514-524.
80. Rabal O, Schneider G, Borrell JI, Teixidó J. Structure-based virtual screening of FGFR inhibitors: cross-decoys and induced-fit effect. BioDrugs 2007; 21: 31-45.
81. Hubbard SR, Schlessinger J, Yeh BK, et al. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997; 276: 955-960.
82. Diller DJ, Li RX. Kinases, homology models, and high throughput docking. J Med Chem 2003; 46: 4638-47.
83. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. ProcNatlAcadSci 2008; 105:3041-46.
84. Ravindranathan KP, Mandiyan V, Ekkati AR, Bae JH, Schlessinger J, Jorgensen WL. Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening. J Med Chem 2010; 53:1662-72.